Hypertension is common in renal transplant recipients (RTR) and may contribute to the high incidence of morbidity and mortality from cardiovascular disease. Its treatment is an important factor necessary to ensure long-term patient and allograft survival. Although all antihypertensive drugs are useful in RTRs, the most commonly used drugs are calcium-channel blockers and renin-angiotensin system inhibitors. This article briefly reviews traditional drugs together with new antihypertensive drugs under development, focusing on their possible advantages in RTRs. In addition, many patents reporting chemical processes and pharmaceutical formulations of these drugs are also summarised. © 2006 Informa UK Ltd.